Clinical Trial Update: ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating evorpacept in combination with trastuzumab and chemotherapy for metastatic HER2-positive breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Evorpacept (ALX148)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: ALX Oncology Inc. | Conditions: Breast Cancer, Metastatic | Phase 2 | Status: RECRUITING